Skip to content
value.today

Imunon, Inc.

IMNN
$5 Mmarket cap on Oct 30, 2026-23.1% since Jan 2024
Compare
World rank
#26,819
Revenue
—
For year ending December-2025
Net income
$-15 M
SEC filing
Employees
20
As of March 30, 2026
SEC filing

Imunon, Inc. in brief

Imunon, Inc. is a listed company in the Biotechnology industry, based in Lawrenceville, New Jersey, USA. Its market value was $5 M on 30 October 2026, which makes it the 26,819th largest listed company in the world and the 4,393rd largest in the USA on this site. It employs about 20 people and Stacy Lindborg is its chief executive. Its shares trade under the symbol IMNN (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Imunon, Inc.

The Imunon brand and product names contained in this document are trademarks, registered trademarks or service marks of Imunon, Inc. or its subsidiary in the United States and certain other countries. This document also contains references to trademarks and service marks of other companies that are the property of their respective owners.

Imunon is a clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms with the aim to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. Imunon is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas®, is developed for the coding of proteins and cytokines in the treatment of solid tumors where an immunological approach is deemed promising. The second modality, PlaCCine®, is developed for the coding of viral antigens that can elicit a strong immunological response. This technology may represent a promising platform for the development of vaccines in infectious diseases.

From the company's annual report filed with the US SEC: read the report

Imunon, Inc. timeline

4 events, 1996–2022
  1. 1996
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 1998
  4. ✎
    Renamed Celsion Corp
    Formerly Cheung Laboratories Inc.
  5. 2022
  6. 💰
    Record revenue of $0 million
    FY2022, the highest of the 5 years on record.
  7. ✎
    Renamed Imunon, Inc.
    Formerly Celsion Corp.

Events of Imunon, Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$3 M$6 M$10 M$13 M2023202420252026

World rank over time

▲ up 4,738 places since 2022
2022-12-25: #31566#31,56620222023-07-30: #31137#31,13720232024-01-05: #31919#31,91920242026-03-08: #12746#12,74620262026-08-01: #23062#23,06220262026-10-13: #26540#26,54020262026-10-30: #26828#26,8282026

Rank in USA: #5,580 (Dec 2022) · #5,363 (Jul 2023) · #4,582 (Jan 2024) · #2,378 (Mar 2026) · #4,064 (Aug 2026) · #4,309 (Oct 2026) · #4,395 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
0.8×
Free cash flow yield
-263.6%
Net margin
—
Operating margin
—
Return on equity
-205.4%
Liabilities / assets
42.6%
Net debt
$-6M
Revenue growth
0.0%
R&D / revenue
2346.0%
Profit per employee
$-725 K

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue $1M, net income $-12M$1MFY18Fiscal year ending Dec 2019: revenue $1M, net income $-17M$1MFY19Fiscal year ending Dec 2020: revenue $1M, net income $-21M$1MFY20Fiscal year ending Dec 2021: revenue $1M, net income $-21M$1MFY21Fiscal year ending Dec 2022: revenue $1M, net income $-36M$1MFY22Fiscal year ending Dec 2023: revenue —, net income $-20M—FY23Fiscal year ending Dec 2024: revenue —, net income $-19M—FY24Fiscal year ending Dec 2025: revenue —, net income $-15M—FY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025——$-15M$-15M—
Dec 2024——$-19M$-19M—
Dec 2023——$-21M$-20M—
Dec 2022$1M0.0%$-25M$-36M-7180.0%
Dec 2021$1M0.0%$-21M$-21M-4154.0%
Dec 2020$1M0.0%$-18M$-21M-4296.0%
Dec 2019$1M0.0%$-21M$-17M-3370.0%
Dec 2018$1M—$-21M$-12M-2376.0%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-14M$0M$-14M$-6.83—
Dec 2024$-19M$0M$-19M$-16.94—
Dec 2023$-19M$0M$-19M$-2.16—
Dec 2022$-23M$0M$-23M$-5.03—
Dec 2021$-16M$0M$-17M$-3.83—
Dec 2020$-16M$0M$-16M$-10.08—
Dec 2019$-20M$0M$-21M$-0.77—
Dec 2018$-7M$0M$-7M$-0.68—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue —, net income $-4M—Dec ’24Three months to Mar 2025: revenue —, net income $-4M—Mar ’25Three months to Jun 2025: revenue —, net income $-3M—Jun ’25Three months to Sep 2025: revenue —, net income $-3M—Sep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $-4M—Dec ’25Three months to Mar 2026: revenue —, net income $-4M—Mar ’26Three months to Jun 2026: revenue —, net income $-3M—Jun ’26Three months to Sep 2026: revenue —, net income $-4M—Sep ’26

Latest quarter to Sep 2026: revenue —, net income $-4M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Imunon, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
—
Operating income
$-15 M
Net income
$-15 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$12 M
Total liabilities
$5 M
Total equity
$7 M

As of December-2025

Top 22 institutional investors in Imunon, Inc.#

As of Sep 30, 2026
22 institutions held 454,832 shares (about 7.0% of the shares outstanding) on Sep 30, 2026. The ten largest hold 6.9%. Source: SEC Form 13F filings, filed through Nov 16, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 22 largest institutional investors in Imunon, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Armistice Capital, LLC270,497+125,730 (+86.85%)4.17%$0 MNov 16, 2026
2Vanguard Capital Management LLC46,9670 (0.00%)0.72%$0 MNov 13, 2026
3Geode Capital Management, LLC41,104+9,475 (+29.96%)0.63%$0 MNov 6, 2026
4Nvest Financial, LLC26,286New0.41%$0 MNov 12, 2026
5State Street Corp15,831New0.24%$0 MNov 12, 2026
6Vanguard Fiduciary Trust Co13,2690 (0.00%)0.20%$0 MNov 13, 2026
7HRT Financial LP11,697New0.18%$0 MNov 13, 2026
8Northern Trust Corp10,3420 (0.00%)0.16%$0 MNov 16, 2026
9Tower Research Capital LLC (TRC)5,596+1,644 (+41.60%)0.09%$0 MNov 16, 2026
10BlackRock, Inc.4,4640 (0.00%)0.07%$0 MNov 13, 2026
11Wells Fargo & Company/mn3,285-57 (-1.71%)0.05%$0 MNov 16, 2026
12UBS Group AG2,027-3,176 (-61.04%)0.03%$0 MNov 10, 2026
13Morgan Stanley1,503-71 (-4.51%)0.02%$0 MNov 13, 2026
14SBI Securities Co., Ltd.1,0270 (0.00%)0.02%$0 MOct 22, 2026
15Citigroup Inc922New0.01%$0 MNov 4, 2026
16Group One Trading LLC60 (0.00%)0.00%$0 MNov 10, 2026
17Osaic Holdings, Inc.3+1 (+50.00%)0.00%$0 MNov 12, 2026
18Northwestern Mutual Wealth Management Co2-1 (-33.33%)0.00%$0 MNov 13, 2026
19Royal Bank Of Canada10 (0.00%)0.00%$0 MNov 16, 2026
20Steigerwald, Gordon & Koch Inc.10 (0.00%)0.00%$0 MNov 12, 2026
21Game Plan Financial Advisors, LLC10 (0.00%)0.00%$0 MNov 10, 2026
22GK Wealth Management LLC1New0.00%$0 MOct 9, 2026

Mutual funds holding Imunon, Inc.#

5 funds hold shares worth $0 M (about 1.1% of the company). Since their previous reports 3 added shares and 1 sold, buying $0 M net.
Mutual funds holding Imunon, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.46,967$0 M0.72%<0.01%+191%Jun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC20,413$0 M0.31%<0.01%+19%May 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC4,744$0 M0.07%<0.01%+50%May 31, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC1,776$0 M0.03%<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC163$0 M<0.01%<0.01%no changeMay 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 5 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Imunon, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$38 K
6 sales, 1 insider
Net, 12 months
-$38 K
open market only
Insiders on file
23
since
$80 K-$21 K$0Aug 2024: bought $80 K (3 trades), sold $0 (0 trades)Aug 24Jun 2026: bought $0 (0 trades), sold $21 K (1 trades)JunJul 2026: bought $0 (0 trades), sold $6 K (2 trades)JulAug 2026: bought $0 (0 trades), sold $12 K (3 trades)Aug
Bought (open market)Sold (open market)Hover a month for the totals
Imunon, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Douglas Vincent FallerChief Medical OfficerGrant or award+1,596$0.845$1 K76,356Form 4
filed Stacy LindborgPresident and CEO, DirectorGrant or award+3,804$0.845$3 K122,581Form 4
filed Michael H. TardugnoExecutive Chairman of Board, DirectorGrant or award+9,969$0.845$8 K128,511Form 4
filed Frederick J. FritzDirectorGrant or award+13$0.845$1128,242Form 4
filed Christine A. PellizzariDirectorGrant or award+13,166$0.845$11 K28,665Form 4
filed James E. DentzerDirectorGrant or award+13,166$0.845$11 K34,197Form 4
filed Donald P. BraunDirectorGrant or award+11,746$0.845$10 K33,643Form 4
filed Stacy LindborgPresident and CEO, DirectorGrant or award+2,603$1.235$3 K118,777Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Imunon, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
215,645
6.3% of shares · 1.49 days to cover
Shares sold short, last 24 reportsAll stocks →

Trading halts

  • 2025-07-24 23:50 UTC, code T3, resumed 13:00 UTC
  • 2025-05-27 13:30 UTC, code LUDP, resumed 13:35 UTC
  • 2025-05-23 14:00 UTC, code LUDP, resumed 14:05 UTC
  • 2025-05-23 13:42 UTC, code LUDP, resumed 13:47 UTC
  • 2025-05-23 13:36 UTC, code LUDP, resumed 13:41 UTC

Fails to deliver

  • : 11,909 shares at $0.83
  • : 12,794 shares at $0.83
  • : 7,933 shares at $0.88
  • : 94 shares at $1.07
  • : 1 shares at $1.28

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Imunon, Inc. scorecard#

Passes 2 of the 4 checks that could be worked out. Fiscal year 2026; market cap of Oct 30, 2026.

  • Valuation1 of 3
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✓Price to book below its peers' median0.8×Price to book 0.8× against Biotechnology's median of 2.9×.
    • –Price to sales below its peers' medianNo Price to sales on file.
    • –Free cash flow yield above 5%No free cash flow yield on file.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growthnot known
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • –Earnings per share grew in the newest yearEarnings per share of two years are not on file.
    • –Net income higher than five years earlierNet income of five years earlier is not on file.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitabilitynot known
    • –Profitable in the newest yearNo net income on file.
    • –Profitable in each of the last five yearsFive years of net income are not on file.
    • –Operating margin above its peers' medianNo operating margin on file.
    • –Return on equity above 15%No return on equity (equity missing or negative).
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial healthnot known
    • –Short-term assets cover short-term liabilitiesCurrent assets and liabilities are not on file.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • –Cash from operations positive in each of the last three yearsThree years of operating cash flow are not on file.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns1 of 1
    • ✓Pays a dividendYesPaid dividends in fiscal 2026.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • –Share count up no more than 2% in a yearShare counts of two years are not on file.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Imunon, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Imunon, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue———0.50.50.50.50.50.5—
Research and development7.8121112111113121315
General and administrative6.97.59.714117.68.09.75.96.5
Operating expenses15192125221921221921
Operating income−15−19−21−25−21−18−21−21−18−21
Interest and finance income—0.50.70.50.00.10.40.4r0.00.0
Interest expense and finance costs——0.25.00.61.3————
Other non-operating income (expense)0.20.50.2−13−1.1−4.81.9−1.2−1.9−1.4
Income before tax1519r−21−37−22−23−19−22−20—
Income tax——−1.3−1.6−1.4−1.8−1.8−10——
Net income attributable to shareholders−14−19−20−36−21−21−17−12−20−22
Earnings per share, basic-6.83-16.94r-2.16-5.03-3.83-10.08r-0.77-0.68-2.72-11.89r
Earnings per share, diluted-6.83-16.94r-2.16-5.03-3.83-10.08r-0.77-0.68-2.72-11.89r
Shares, weighted average (basic)2.11.1r9.07.15.4—————
Shares, weighted average (diluted)2.11.1r9.07.15.42.1r22187.61.9r
Balance sheet
Cash and cash equivalents8.85.95.81120176.913112.6
Short-term investments——9.82130—7.914r13r1.7
Other current assets—————————0.1
Current assets118.01837r52191628244.5
Property, plant and equipment0.50.50.80.50.50.30.40.20.20.5
Right-of-use (leased) assets1.01.11.60.20.71.01.41.1——
Goodwill—————2.02.02.02.02.0
Other intangible assets—————0.10.30.60.81.0
Non-current assets——————22192326
Total assets129.72244743838474831
Accounts payable1.41.33.53.62.52.22.93.03.42.9
Current liabilities4.64.87.4106.86.87.96.16.28.4
Lease liabilities (non-current)0.60.71.1—0.20.71.1———
Total liabilities5.25.58.515181924262124
Retained earnings−421−407−388−369−333−312−291−274−262−241
Shareholders' equity7.14.2132956191521276.7
Total liabilities and equity129.72244743838474831
Shares outstanding3.41.0r9.47.45.82.7r2319172.2r
Cash-flow statement
Depreciation and amortization—0.20.20.70.70.70.70.40.61.0
Share-based compensation0.10.50.82.7r3.81.92.34.61.11.5
Cash from operating activities−14−19−19−23r−16−16−20−7.0−17−18
Capital expenditure−0.3−0.0−0.5−0.3−0.3−0.0−0.3−0.1−0.0−0.1
Cash from investing activities−0.39.8118.3r−307.95.9−1.6−119.1
Debt issued—————1.3————
Debt repaid—————−1.3————
Shares issued149.12.86.7r53237.80.9——
Cash from financing activities179.1−3.66.7r55187.811362.7
Change in cash2.90.0−12−8.18.410−6.51.98.8−6.6
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Executive pay at Imunon, Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$1.0 M
Dr. Lindborg
Other top executives, average
$598 K
the CEO earned 1.7× this
$100 invested is now
$18
Imunon, Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Dr. Lindborg$1.0 M$751 K$598 K$18
2024Stacy Lindborg$1.2 M$1.1 M$567 K$63
2023Dr. Le Goff$1.1 M$911 K$680 K$45

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at Imunon, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling
  • Delisting noticeFiling
  • Delisting noticeFiling

Delisting notice 3 · Directors and officers 8 · Material agreement 5 · New debt 1 · Unregistered share sale 3 · Shareholder rights changed 2 · Bylaws or fiscal year changed 4 · Shareholder vote 2 · Results announced 6

Imunon, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Material agreement8-K
Material agreementUnregistered share saleBylaws or fiscal year changed8-K
Results announced8-K
Directors and officers8-K
Directors and officers8-K
Directors and officersShareholder vote8-K
Material agreementNew debtUnregistered share saleBylaws or fiscal year changed8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Directors and officers8-K
Directors and officers8-K
Material agreement8-K
Results announced8-K
Delisting notice8-K
Results announced8-K
Shareholder rights changedBylaws or fiscal year changed8-K
Delisting noticeDirectors and officers8-K
Shareholder rights changedBylaws or fiscal year changedShareholder vote8-K
Directors and officers8-K
Delisting notice8-K
Material agreementUnregistered share sale8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026

Acquisitions and funding#

1 private funding rounds before listing

Private share sales · funding history

Private share sales of Imunon, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
May 2025$3 MPrivate placement after listing$2 to $10 million3equity, optionsSEC
Aug 2024$10 MPrivate placement after listing$10 to $50 million4equity, optionsSEC
Jun 2015$5 MPrivate placement after listing$2 to $10 million3optionsSEC
Jun 2014$9 MPrivate placement after listing$2 to $10 million1equitySEC
Jun 2011$9 MNo. 1$2 to $10 million31equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

How Imunon, Inc. compares in Biotechnology

  • Market cap$5 M · higher than 6% of 726
  • Revenue growth0.0% · higher than 42% of 438
  • Price / book0.8× · lower than 83% of 534

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Imunon, Inc.🇺🇸$5 M——0.0%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 30, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of March 30, 2026
Profile updated:
Nov 19, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report, GLEIF register; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Imunon, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Imunon, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Imunon, Inc.? Suggest a correction